Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03903276
Other study ID # 90466098200
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 1, 2019
Est. completion date December 20, 2019

Study information

Verified date August 2020
Source Universidade Metodista de Piracicaba
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Among all cancers, lung cancer is the most common disease on the planet, accounting for 13% of the cases, and leading the number of deaths from malignant diseases. In Brazil, it is estimated that its incidence between 2018 and 2019 could be 18,704 new cases in men and 12,503,000 new cases in women. These data take into account an estimated risk of 18.16 new cases for 100,000 men and 11.81 for 100,000 women, respectively occupying the second and fourth most frequent cases of the disease according to gender .

Surgeries, however aggressive they may be, are one of the most viable alternatives for patients with PC, provided it is performed in the milder or early phase of the disease, since after such period this procedure may have a period degree greater than the other forms of treatment.

As a consequence, the injuries that the surgical procedure can cause to patients, pain is one of the most influential in the patient's quality of life. It can lead the individual to a marked state of disability both functional and psychological, thus being determinant for the suffering related to the disease, thus comprising its multifactorial character, involving physical, emotional, socio-cultural and environmental aspects .

For the control of pain, physiotherapy appears with features such as transcutaneous nerve electrostimulation, where its use for the suppression of pain has become quite feasible due mainly to the ease of its handling, to be noninvasive and to serve to reduce acute pain and chronic.

The use of conventional transcutaneous nerve electrostimulation to support the use of analgesics reduced the intensity of pain in patients of the second day of thoracotomy, but for a longer extension of their effects, it would take a longer time to apply the resource, something around 24 -48 hours.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date December 20, 2019
Est. primary completion date December 20, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Patients diagnosed with Primary Lung Cancer; male over 18 years and less than 59 years old, in an immediate postoperative period in the ward of the Hospital thoracic clinic.

- Evaluation of pain through the visual analogue scale equal to or greater than moderate or intense.

- Percentage equal to or greater than 70% in all the items assessed by the Performance Status functional capacity scale.

Exclusion Criteria:

- Patients with immediate postoperative complications

- Unconscious or sedation patients

- Patients with invasive mechanical ventilation

- Patients who present lesions that make it difficult to handle and place electrodes.

- Patients who use pacemakers and metal plates.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
rehabilitation
Tens

Locations

Country Name City State
Brazil Universidade do Estado do Pará Belém Pará

Sponsors (2)

Lead Sponsor Collaborator
Universidade Metodista de Piracicaba Universidade do Estado do Pará

Country where clinical trial is conducted

Brazil, 

References & Publications (4)

Ainsworth L, Budelier K, Clinesmith M, Fiedler A, Landstrom R, Leeper BJ, Moeller L, Mutch S, O'Dell K, Ross J, Radhakrishnan R, Sluka KA. Transcutaneous electrical nerve stimulation (TENS) reduces chronic hyperalgesia induced by muscle inflammation. Pain — View Citation

Hochberg U, Elgueta MF, Perez J. Interventional Analgesic Management of Lung Cancer Pain. Front Oncol. 2017 Feb 14;7:17. doi: 10.3389/fonc.2017.00017. eCollection 2017. Review. — View Citation

Rushton DN. Electrical stimulation in the treatment of pain. Disabil Rehabil. 2002 May 20;24(8):407-15. Review. — View Citation

Spiro SG, Gould MK, Colice GL; American College of Chest Physicians. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition). Ches — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Pain perception Visual analogue scale - EVA: consists of checking the intensity of pain in patients at the moment it is being evaluated. Such a tool consists of a line with the ends numbered from 0 to 10, and from 0 to 2 it is considered light pain; 3 to 7 moderate pain; and 8 to 10 severe pain post treatment in 3 days
Primary Functional capacity Functional capacity scale Performance Status- PS: aims to monitor the clinical evolution of a disease by joining the Karnofsky scale and the Zubrod or ECOG scale. Karnofsky's scale or index describes increasing levels of activities and independence of the individual stipulated values between 0 and 100, zero meaning no functionality or death and 100 representing the maximum degree of physical ability to perform activities. The Zubrod or ECOG scale quantified between 0 and 4, where 0 means 0 indicates that the individual is fully active for the performance of his activities and 4 assigning to the dead patient. Such scales are widely used for the evaluation of oncological patients, being somewhat complementary, therefore used together post treatment in 3 days
See also
  Status Clinical Trial Phase
Recruiting NCT06152419 - Patient Education Videos to Improve Patients' Experience During Radiotherapy Treatment: a National Project N/A
Recruiting NCT04105647 - Lifestyle Modification Program for Lung Cancer Patients - A Pilot Study N/A
Completed NCT05732350 - Exploratory Drug Interaction Study Between SMIs and DOACs
Active, not recruiting NCT04300244 - Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma Phase 2
Recruiting NCT05311709 - Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities Phase 2
Active, not recruiting NCT04396457 - Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901 Phase 2
Recruiting NCT06391749 - Clinical Validation of an MCED Test in Symptomatic Populations (K-ACCELERATE)
Not yet recruiting NCT03910283 - Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer N/A
Recruiting NCT03301493 - Genomic Testing and Resulting Medical Decisions
Completed NCT04788147 - Performance and Safety of Biology-Guided Radiotherapy Using the RefleXion Medical Radiotherapy System (BIOGUIDE-X) N/A
Not yet recruiting NCT06035731 - Evaluation of the Medical Service by Socio-aesthetics in Oncology N/A
Recruiting NCT03274349 - Whole Body Electromyostimulation and Nutritional Therapy for Patients With Esophageal and Bronchial Carcinoma N/A
Recruiting NCT05830097 - A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT02991677 - Exercise Effect on Chemotherapy-Induced Neuropathic Pain N/A
Completed NCT04971304 - Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars
Recruiting NCT04859400 - Influence of a Home-based Nutrition and Exercise Program on Quality of Life of Palliative Cancer Outpatients N/A
Recruiting NCT05948865 - A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT04270890 - Investigation of an Abdominal Compression Device N/A
Not yet recruiting NCT05154474 - Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy
Not yet recruiting NCT05857995 - Precision Lung Cancer Survivorship Care Intervention N/A